S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain

Medical Stocks List

This page shows information about the 50 largest medical stocks including UnitedHealth Group, Eli Lilly and, Johnson & Johnson, and Novo Nordisk A/S. Learn more about medical stocks.

UnitedHealth Group logo

#1 - UnitedHealth Group

NYSE:UNH
Stock Price: $478.82 (-$0.41)
Market Cap: $445.80 billion
P/E Ratio: 21.9
Dividend Yield: 1.38%
Consensus Rating: Buy (14 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $600.88 (25.5% Upside)
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minnetonka, MN.
Eli Lilly and logo

#2 - Eli Lilly and

NYSE:LLY
Stock Price: $442.38 (+$4.49)
Market Cap: $419.94 billion
P/E Ratio: 70.3
Dividend Yield: 1.03%
Consensus Rating: Buy (11 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $415.75 (-6.0% Upside)
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Johnson & Johnson logo

#3 - Johnson & Johnson

NYSE:JNJ
Stock Price: $158.91 (+$0.43)
Market Cap: $412.96 billion
P/E Ratio: 33.2
Dividend Yield: 2.85%
Consensus Rating: Hold (6 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $173.00 (8.9% Upside)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Novo Nordisk A/S logo

#4 - Novo Nordisk A/S

NYSE:NVO
Stock Price: $170.54 (+$1.99)
Market Cap: $385.93 billion
P/E Ratio: 44.9
Dividend Yield: 1.00%
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $383.33 (124.8% Upside)
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Merck & Co., Inc. logo

#5 - Merck & Co., Inc.

NYSE:MRK
Stock Price: $115.49 (+$1.49)
Market Cap: $293.05 billion
P/E Ratio: 22.6
Dividend Yield: 2.56%
Consensus Rating: Buy (16 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $120.75 (4.6% Upside)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
AbbVie logo

#6 - AbbVie

NYSE:ABBV
Stock Price: $145.11 (+$1.67)
Market Cap: $256.02 billion
P/E Ratio: 34.3
Dividend Yield: 4.13%
Consensus Rating: Hold (6 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $163.40 (12.6% Upside)
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
AstraZeneca logo

#7 - AstraZeneca

NASDAQ:AZN
Stock Price: $74.79 (+$0.58)
Market Cap: $231.83 billion
P/E Ratio: 49.2
Dividend Yield: 2.58%
Consensus Rating: Hold (4 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $126.00 (68.5% Upside)
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Novartis logo

#8 - Novartis

NYSE:NVS
Stock Price: $100.81 (+$0.46)
Market Cap: $213.68 billion
P/E Ratio: 31.0
Dividend Yield: 2.26%
Consensus Rating: Hold (3 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $82.25 (-18.4% Upside)
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

#9 - Pfizer

NYSE:PFE
Stock Price: $36.77 (+$0.29)
Market Cap: $207.58 billion
P/E Ratio: 7.2
Dividend Yield: 4.50%
Consensus Rating: Hold (4 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $47.33 (28.7% Upside)
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Thermo Fisher Scientific logo

#10 - Thermo Fisher Scientific

NYSE:TMO
Stock Price: $527.38 (+$3.84)
Market Cap: $203.42 billion
P/E Ratio: 34.4
Dividend Yield: 0.27%
Consensus Rating: Buy (9 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $627.91 (19.1% Upside)
Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industri
Abbott Laboratories logo

#11 - Abbott Laboratories

NYSE:ABT
Stock Price: $108.93 (+$0.46)
Market Cap: $189.42 billion
P/E Ratio: 33.1
Dividend Yield: 1.88%
Consensus Rating: Buy (11 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $122.37 (12.3% Upside)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Sanofi logo

#12 - Sanofi

NASDAQ:SNY
Stock Price: $55.03 (+$1.17)
Market Cap: $138.78 billion
P/E Ratio: 19.7
Dividend Yield: 2.29%
Consensus Rating: Buy (6 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $94.50 (71.7% Upside)
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Bristol-Myers Squibb logo

#13 - Bristol-Myers Squibb

NYSE:BMY
Stock Price: $65.84 (+$0.14)
Market Cap: $138.32 billion
P/E Ratio: 19.2
Dividend Yield: 3.47%
Consensus Rating: Hold (7 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $79.43 (20.6% Upside)
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Amgen logo

#14 - Amgen

NASDAQ:AMGN
Stock Price: $223.42 (-$0.81)
Market Cap: $119.38 billion
P/E Ratio: 15.2
Dividend Yield: 3.80%
Consensus Rating: Hold (6 Buy Ratings, 3 Hold Ratings, 4 Sell Ratings)
Consensus Price Target: $250.94 (12.3% Upside)
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Medtronic logo

#15 - Medtronic

NYSE:MDT
Stock Price: $89.33 (+$0.31)
Market Cap: $118.85 billion
P/E Ratio: 29.4
Dividend Yield: 3.06%
Consensus Rating: Hold (4 Buy Ratings, 11 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $90.11 (0.9% Upside)
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Intuitive Surgical logo

#16 - Intuitive Surgical

NASDAQ:ISRG
Stock Price: $313.61 (+$1.38)
Market Cap: $109.89 billion
P/E Ratio: 85.7
Consensus Rating: Buy (15 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $300.50 (-4.2% Upside)
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.
Elevance Health logo

#17 - Elevance Health

NYSE:ELV
Stock Price: $457.83 (+$2.82)
Market Cap: $108.53 billion
P/E Ratio: 17.8
Dividend Yield: 1.30%
Consensus Rating: Buy (12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $572.19 (25.0% Upside)
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Stryker logo

#18 - Stryker

NYSE:SYK
Stock Price: $285.37 (+$0.11)
Market Cap: $108.33 billion
P/E Ratio: 41.5
Dividend Yield: 1.05%
Consensus Rating: Buy (12 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $300.86 (5.4% Upside)
Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
Gilead Sciences logo

#19 - Gilead Sciences

NASDAQ:GILD
Stock Price: $78.85 (+$0.64)
Market Cap: $98.35 billion
P/E Ratio: 17.8
Dividend Yield: 3.84%
Consensus Rating: Buy (9 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $91.00 (15.4% Upside)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Vertex Pharmaceuticals logo

#20 - Vertex Pharmaceuticals

NASDAQ:VRTX
Stock Price: $341.70 (+$2.24)
Market Cap: $88.00 billion
P/E Ratio: 27.2
Consensus Rating: Buy (10 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $352.59 (3.2% Upside)
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Regeneron Pharmaceuticals logo

#21 - Regeneron Pharmaceuticals

NASDAQ:REGN
Stock Price: $759.05 (+$11.57)
Market Cap: $82.98 billion
P/E Ratio: 20.6
Consensus Rating: Buy (19 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $850.21 (12.0% Upside)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Zoetis logo

#22 - Zoetis

NYSE:ZTS
Stock Price: $179.55 (-$0.17)
Market Cap: $82.97 billion
P/E Ratio: 40.5
Dividend Yield: 0.84%
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $221.14 (23.2% Upside)
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.
HCA Healthcare logo

#23 - HCA Healthcare

NYSE:HCA
Stock Price: $282.47 (+$3.07)
Market Cap: $77.73 billion
P/E Ratio: 14.2
Dividend Yield: 0.86%
Consensus Rating: Buy (17 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $298.17 (5.6% Upside)
HCA Healthcare, Inc. is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities. The firm operates general and acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services, and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was founded by Dr. Thomas F. Frist, Jr in 1968 and is headquartered in Nashville, TN.
Boston Scientific logo

#24 - Boston Scientific

NYSE:BSX
Stock Price: $53.64 (+$0.20)
Market Cap: $75.10 billion
P/E Ratio: 90.9
Consensus Rating: Buy (14 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $53.89 (0.5% Upside)
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.
GSK logo

#25 - GSK

NYSE:GSK
Stock Price: $35.61 (+$0.40)
Market Cap: $72.91 billion
P/E Ratio: 4.3
Dividend Yield: 3.86%
Consensus Rating: Hold (4 Buy Ratings, 4 Hold Ratings, 3 Sell Ratings)
Consensus Price Target: $1,576.88 (4,328.2% Upside)
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Becton, Dickinson and logo

#26 - Becton, Dickinson and

NYSE:BDX
Stock Price: $251.88 (+$0.31)
Market Cap: $71.54 billion
P/E Ratio: 47.3
Dividend Yield: 1.45%
Consensus Rating: Buy (7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $276.60 (9.8% Upside)
Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Aetna logo

#27 - Aetna

NYSE:AET
Stock Price: $212.70
Market Cap: $69.64 billion
P/E Ratio: 21.6
Dividend Yield: 0.94%
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
Humana logo

#28 - Humana

NYSE:HUM
Stock Price: $513.52 (-$0.35)
Market Cap: $64.16 billion
P/E Ratio: 20.9
Dividend Yield: 0.69%
Consensus Rating: Buy (15 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $597.37 (16.3% Upside)
Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.
Allergan logo

#29 - Allergan

NYSE:AGN
Stock Price: $0.00
Market Cap: $63.50 billion
Dividend Yield: 1.53%
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Shire logo

#30 - Shire

NASDAQ:SHPG
Stock Price: $179.20
Market Cap: $54.71 billion
P/E Ratio: 11.8
Dividend Yield: 0.19%
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
McKesson logo

#31 - McKesson

NYSE:MCK
Stock Price: $397.67 (-$0.19)
Market Cap: $53.92 billion
P/E Ratio: 15.8
Dividend Yield: 0.54%
Consensus Rating: Buy (7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $430.17 (8.2% Upside)
McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment br
Edwards Lifesciences logo

#32 - Edwards Lifesciences

NYSE:EW
Stock Price: $87.93 (+$0.52)
Market Cap: $53.30 billion
P/E Ratio: 36.5
Consensus Rating: Hold (7 Buy Ratings, 10 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $89.63 (1.9% Upside)
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Express Scripts logo

#33 - Express Scripts

NASDAQ:ESRX
Stock Price: $92.33
Market Cap: $52.06 billion
P/E Ratio: 13.0
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Takeda Pharmaceutical logo

#34 - Takeda Pharmaceutical

NYSE:TAK
Stock Price: $16.18 (+$0.12)
Market Cap: $51.20 billion
P/E Ratio: 21.0
Dividend Yield: 3.34%
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $24.67 (52.5% Upside)
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Moderna logo

#35 - Moderna

NASDAQ:MRNA
Stock Price: $126.24 (+$0.91)
Market Cap: $48.12 billion
P/E Ratio: 10.9
Consensus Rating: Hold (7 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $179.13 (41.9% Upside)
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
DexCom logo

#36 - DexCom

NASDAQ:DXCM
Stock Price: $117.13 (-$1.90)
Market Cap: $45.40 billion
P/E Ratio: 167.3
Consensus Rating: Buy (11 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $126.81 (8.3% Upside)
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
Biogen logo

#37 - Biogen

NASDAQ:BIIB
Stock Price: $308.48 (+$3.03)
Market Cap: $44.65 billion
P/E Ratio: 14.3
Consensus Rating: Buy (21 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $328.38 (6.5% Upside)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
IDEXX Laboratories logo

#38 - IDEXX Laboratories

NASDAQ:IDXX
Stock Price: $488.10 (-$3.96)
Market Cap: $40.46 billion
P/E Ratio: 58.7
Consensus Rating: Buy (6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $527.86 (8.1% Upside)
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, a
Alexion Pharmaceuticals logo

#39 - Alexion Pharmaceuticals

NASDAQ:ALXN
Stock Price: $182.50
Market Cap: $40.34 billion
P/E Ratio: 59.6
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Alcon logo

#40 - Alcon

NYSE:ALC
Stock Price: $81.79 (+$0.97)
Market Cap: $40.08 billion
P/E Ratio: 120.3
Consensus Rating: Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $83.18 (1.7% Upside)
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.
Haleon logo

#41 - Haleon

NYSE:HLN
Stock Price: $8.65 (+$0.17)
Market Cap: $39.94 billion
Dividend Yield: 0.70%
Consensus Rating: Hold (8 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $364.00 (4,108.1% Upside)
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Seagen logo

#42 - Seagen

NASDAQ:SGEN
Stock Price: $193.30 (-$0.85)
Market Cap: $36.24 billion
Consensus Rating: Hold (6 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $190.47 (-1.5% Upside)
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
GE HealthCare Technologies logo

#43 - GE HealthCare Technologies

NASDAQ:GEHC
Stock Price: $79.34 (-$0.35)
Market Cap: $36.07 billion
Consensus Rating: Buy (5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $92.40 (16.5% Upside)
GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is based in Chicago, Illinois.
Centene logo

#44 - Centene

NYSE:CNC
Stock Price: $65.40 (-$0.40)
Market Cap: $35.89 billion
P/E Ratio: 24.8
Consensus Rating: Buy (12 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $92.00 (40.7% Upside)
Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The company was founded in 1984 and is headquartered in St. Louis, MO.
AmerisourceBergen logo

#45 - AmerisourceBergen

NYSE:ABC
Stock Price: $173.39 (-$1.43)
Market Cap: $35.11 billion
P/E Ratio: 22.3
Dividend Yield: 1.11%
Consensus Rating: Buy (12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $181.62 (4.7% Upside)
AmerisourceBergen Corp. engages in the provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, and long-term care and alternate site pharmacies. The Other segment focuses on global commercialization services and animal health, and includes AmerisourceBergen Consulting Services ABCS, World Courier, and MWI. The company was founded by in Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
ResMed logo

#46 - ResMed

NYSE:RMD
Stock Price: $224.51 (+$0.30)
Market Cap: $32.99 billion
P/E Ratio: 38.2
Dividend Yield: 0.78%
Consensus Rating: Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $259.00 (15.4% Upside)
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Illumina logo

#47 - Illumina

NASDAQ:ILMN
Stock Price: $204.86 (+$3.57)
Market Cap: $32.39 billion
Consensus Rating: Hold (8 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $253.70 (23.8% Upside)
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Zimmer Biomet logo

#48 - Zimmer Biomet

NYSE:ZBH
Stock Price: $135.00 (-$0.02)
Market Cap: $28.16 billion
P/E Ratio: 63.1
Dividend Yield: 0.71%
Consensus Rating: Hold (6 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $143.67 (6.4% Upside)
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm's orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medica
Cerner logo

#49 - Cerner

NASDAQ:CERN
Stock Price: $94.92
Market Cap: $27.92 billion
P/E Ratio: 47.7
Dividend Yield: 1.14%
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri.
Genmab A/S logo

#50 - Genmab A/S

NASDAQ:GMAB
Stock Price: $41.64 (+$0.96)
Market Cap: $27.47 billion
P/E Ratio: 37.5
Consensus Rating: Hold (3 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $631.96 (1,417.7% Upside)
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
Health Care Stocks Explained: Why You Might Want to Invest

Do certain sectors seem about as appetizing as eating a soggy Slim Jim? The last thing you want to do is sink your money into a sector that has no upward mobility. It's wise to be careful, particularly during these inflationary times.

But what about investing in the health care sector? It's worth digging into health care stocks because of their ability to transcend what's happening in the economy.  

In this article, we'll take a look at health care stocks during inflationary times, why a particular health care stock may make a good investment, when these particular stocks do well, the stock performance of some top health care stocks and how to invest in these particular stocks. We'll also help you put some health care stocks on your to-research list.

Let's get started. 

Between the start of 1991 and the end of 2019, inflation on a year-over-year basis averaged about 2.3% a month and only went over 5% a handful of times. Not so over the past two years. 

The Consumer Price Index for All Urban Consumers did not change in July 2022 after rising 1.3% in June, according to the U.S. Bureau of Labor Statistics. The all items index increased 8.5% over the past year.

A quick summary in July 2022: 

  • The gasoline index fell 7.7% in July 
  • The energy index fell 4.6% 
  • The food index increased 1.1% 
  • The food at home index rose 1.3%
  • The index for all items (except for food and energy) rose 0.3% 

Some indexes increased, according to the Bureau of Labor Statistics (shelter, medical care, motor vehicle insurance, household furnishings and operations, new vehicles and recreation) and some declined (airfare, used cars and trucks, communication and apparel).

Despite the fact that inflation has been low over the past decades, health care stocks remain one of the most important inflation mediators due to the worldwide aging population, advanced technologies and breakthroughs in clinical trials also encourage success in the sector. Health care has been known as one of the best defensive sectors because they have typically been unchanged due to economic demands.

As with anything else, it's important to evaluate a wide variety of stock fundamentals before you invest. However, in general, it's possible to bank on health care companies because they typically provide returns in a wide variety of markets. 

The general public always needs doctors and insurance companies, and the health care sector can help change the tide of your overall investment portfolio. It's no secret that the pandemic propelled health care stocks further, helping people get the products and services they needed. You'll also likely find cheap health care stocks and fat dividends that come along with them as well.

Shares of U.S. health care companies can do well in both good and poor economic times compared to other typically popular defensive sectors.

If you're curious about health care stocks in general, you can take a look at the health care index (SPXHC). The S&P 500 sectors have ebbed and flowed, including health care. Energy (SPNY) as well as value stocks (IVX) increased.  

Health care stocks respond well in a few specific cases, including due to the aging population and Baby Boomers, people living with long-term diseases, epidemics, advances in technology, global and personalized medicine and other factors, according to a Reuters article.

Investing in healthcare stocks can provide excellent returns, but many factors can affect stock prices. Certain downsides to health care stocks may impinge on their ability to deliver returns to investors. The roadblocks that could cause health care stocks to do well include a single-payer system, the uninsured, cost roadblocks and consumerism.  

U.S. health care spending grew 9.7% in 2020, at a rate of $4.1 trillion or $12,530 per person, according to the American Medical Association. U.S. spending on health care declined for the first time in 60 years in Q1 of 2022 and fell 1.7% year over year as health care prices fell relative to inflation, according to a recent Altarum report.  

According to Modern Healthcare, health care prices in general should rise by 3.6% in 2022 and boost overall healthcare spending growth 4.6% to $4.5 trillion. 

Prices grew: 

  • 2.7% in 2021
  • 3.1% in 2020
  • 1.1% in 2019

A recent AHA report showed hospitals have experienced surging costs in items and resources required to care for patients since the start of the COVID-19 pandemic. 

Expenses per patient rose as follows:

  • Labor: 19.1% between 2019 and 2021
  • Travel nurse costs: 39% of nurse labor expenses by January 2022
  • Supply costs: 21% per patient 
  • Median drug costs: 37% per patient
  • Intensive care unit medical supply costs: 32% per patient

These facts and figures can help health care stock performance go up and/or down. It's a good idea to keep them in mind as you evaluate each stock on an individual basis.

Let's take a look at three top health care stock examples in order to help you choose the right investments for your portfolio. 

UnitedHealth Group Inc. (NYSE: UNH), a diversified health care company, offers a wide range of services, including: 

  • Consumer-oriented health benefit plans
  • Services for national, public sector and mid-sized employers
  • Services small businesses 
  • Preventive, acute health care and chronic disease services
  • Medicaid plans
  • Children's health insurance and health care programs
  • Health and dental benefits
  • Hospital and clinical services
  • Networks of care provider specialists
  • Software and information products
  • Advisory consulting arrangements
  • Managed services outsourcing contracts 
  • Pharmacy care services and programs

In Q2, UnitedHealth Group showed revenues of $80.3 billion, which grew 13% year over year. Earnings from operations were $7.1 billion, a growth of 19% since last year. Cash flows from operations were $6.9 billion, 1.3 times net income. 

Johnson & Johnson (NYSE: JNJ) researches, develops and manufactures products under a wide variety of brands, including JOHNSON'S, AVEENO, LISTERINE, CLEAN & CLEAR, NEUTROGENA, OGX, TYLENOL, SUDAFED, BENADRYL, ZYRTEC, MOTRIN IB, NICORETTE, PEPCID, STAYFREE, CAREFREE, BAND-AID and NEOSPORIN. 

The company creates treatments for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis, HIV/AIDS and COVID-19, mood disorders, neurodegenerative disorders, schizophrenia, cardiovascular diseases and more.

Total sales for Johnson & Johnson grew 3% to $24 billion with operational growth of 8% and adjusted operational growth of 8.1%.

Eli Lilly and Company (NYSE: LLY) develops and sells pharmaceuticals worldwide including the following major brands: 

  • Basaglar
  • Humalog
  • Humulin
  • Jardiance
  • Trajenta
  • Trulicity
  • Cyramza 
  • Erbitux
  • Retevmo
  • Cymbalta
  • Zyprexa
  • Cialis 

Lilly's revenue in Q2 2022 decreased 4%. Total revenue grew 6%, including the U.S. approval and launch of Mounjaro for type 2 diabetes. Trulicity, Verzenio, Jardiance, Taltz, Retevmo, Mounjaro, Emgality, Olumiant, Tyvyt and Cyramza grew 20% and represented 67% of revenue in Q2 2022.

EPS decreased 31% to $1.05 on a reported basis and decreased 32% to $1.25 on a non-GAAP basis. The FDA approved Mounjaro® (tirzepatide) for adults with type 2 diabetes.

Lilly and Incyte's Olumiant® (baricitinib) also received approval, and so did Olumiant for certain patients with COVID-19. The company also announced plans to invest $2.1 billion in two new Indiana manufacturing sites.

Let's take a comprehensive look at how you may want to approach investing in health care stocks.

Digging into the metrics of individual stocks can help you decide how to choose investments you may want to invest in. Consider taking a look at dividend yield, earnings per share and price-to-earnings ratio. There are other metrics you may want to take a look at, but we'll go over the definition of these items. 

  • Dividend yield: The dividend yield tells you how much the company yields in dividends. Analyze the dividends per share divided by the current share price. High-yield dividends can be risky, so determine whether competitors have a much higher dividend yield than the stocks you're considering.
  • Earnings per share (EPS): The earnings per share (EPS) shows how many outstanding shares of stock a company has. You can calculate it by finding out a company's quarterly or annual net income and dividing by the number of outstanding shares of stock it owns.
  • Price-to-earnings (P/E) ratio: The price-to-earnings (P/E) ratio helps show you whether a company is fairly valued. To find the P/E ratio, you can divide a company's share price by its earnings per share.

Do you have a brokerage account? If not, open a brokerage account and fund it. You can choose from three types of brokerages, including online brokers, discount brokers and full-service brokers. Let's take a look at the definition of these three options: 

  • Online brokers: Online brokers offer an online option for investing. You can typically depend on speed, ease of use and low commissions with an online brokerage.
  • Discount broker: A discount broker performs buy and sell orders at lower commission rate compared to full-service brokers.
  • Full-service broker: Full-service brokerages provide a wide range of investment services, including tax tips, research and investing on their behalf, to name a few.

No matter which direction you prefer to go, it's a good idea to take a look at the fees involved, platforms available to you and more. You want to be sure you choose the right option for your needs.

Choose the number of shares you want to purchase and hit the "buy" button. Choose the right investments that meet your specific goals and investment timeline. Consider investing on a monthly basis in order to build on compound interest over the long term. 

The healthcare sector offers a wide range of large and small companies to invest in. However, you can invest in more than just stocks. You can invest in mutual funds and exchange-traded funds (ETFs) to add diversification to your holdings. An ETF works like a mutual fund — a pooled investment — but you can buy and sell at any time during the trading day, like a stock. 

Here is a list of health care ETFs you may want to consider investing in:

More Stock Ideas from MarketBeat

My Account -